Corcept Q4 product revenue hits USD 202.1 million +37% tablets sold

Corcept reported Q4 2025 product revenue, net of USD 202.1 million, up 11.1%, and FY 2025 revenue of USD 761.4 million, up 12.8%. Q4 2025 net income was USD 24.3 million and diluted EPS was USD 0.20; FY 2025 net income was USD 99.7 million and diluted EPS was USD 0.82. Cash and investments were USD 532.4 million at December 31, 2025, and Corcept said it paid USD 245.9 million in 2025 to repurchase common stock under its buyback program (including net impacts from employee equity activity). In its Cushing’s syndrome business, Corcept said 2025 saw a 37% increase in tablets sold, driven by a record number of new prescriptions and prescribers, though growth was constrained by capacity limits at its prior specialty pharmacy vendor and disruptions during a Q4 transition to a new specialty pharmacy; the transition is now complete and February is tracking to be a record month for new patient starts. On the pipeline, Corcept said it is engaged with the FDA on the path forward for relacorilant in Cushing’s syndrome following a Complete Response Letter, and noted an FDA PDUFA date of July 11, 2026 for its NDA for relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer; the EMA is reviewing the corresponding MAA, with approval expected by the end of 2026. Corcept also highlighted upcoming data readouts, including MOMENTUM results at ACC in March, and results expected by the end of 2026 from BELLA (advanced ovarian cancer) and MONARCH (MASH), and said it plans to start a Phase 3 trial of dazucorilant in ALS by mid-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20260224796156) on February 24, 2026, and is solely responsible for the information contained therein.